Development and characterization of a novel ELISA based assay for the quantitation of sub-nanomolar levels of neoepitope exposed NITEGE-containing aggrecan fragments

被引:13
作者
Carter, Quincy L.
Dotzlaf, Joe
Swearingen, Craig
Brittain, Isabelle
Chambers, Mark
Duffin, Kevin
Mitchell, Peter
ThirunavukkaraSU, Kannan
机构
[1] Eli Lilly & Co, Lilly Res Lab, Greenfield, IN 46140 USA
[2] Eli Lilly & Co, Lilly Res Lab, Musculoskeletal Drug Hunting Team, Indianapolis, IN 46285 USA
关键词
aggrecan; aggrecanase; biomarker; neoepitope; NITEGE;
D O I
10.1016/j.jim.2007.08.018
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Osteoarthritis (OA) is associated with the degradation of aggrecan by aggrecanases (e.g. ADAMTS-4, ADAMTS-5) ultimately leading, to the reduction of daily physical activity in aged individuals. The cleavage of aggrecan by aggrecanases generates a series of neoepitope exposed fragments (e.,. NITEGE) in both animal models and osteoarthritic patients. These aggrecan fragments can be used for identifying disease associated biomarkers for the purpose of measuring the efficacy of therapeutic agents in vivo. A monoclonal antibody, 681-3 mab was developed which recognizes the C-terminal neoepitope NITEGE following aggrecan cleavage by aggrecanases. The 681-3 mab has a K-D of 4.03 x 10(-10) M as determined by Biacore analysis. A polyclonal antibody, NEP522 which specifically binds to intact aggrecan was also developed. These antibodies were used to develop a highly sensitive assay with lower detection limits of 125 pM which was capable of detecting NITEGE fragments in ADAMTS-4/5 digested human aggrecan and in IL-1 alpha stimulated bovine nasal cartilage disk cultures. The NITEGE 681-3/NEP522 sandwich ELISA has applications for screening compounds for aggrecanase(s) inhibitory activity, selection of appropriate OA models, the evaluation of compound efficacy in vivo, as well as the potential to stratify patients for clinical trial design. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:162 / 168
页数:7
相关论文
共 21 条
[1]   Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family [J].
Abbaszade, I ;
Liu, RQ ;
Yang, F ;
Rosenfeld, SA ;
Ross, OH ;
Link, JR ;
Ellis, DM ;
Tortorella, MD ;
Pratta, MA ;
Hollis, JM ;
Wynn, R ;
Duke, JL ;
George, HJ ;
Hillman, MC ;
Murphy, K ;
Wiswall, BH ;
Copeland, RA ;
Decicco, CP ;
Bruckner, R ;
Nagase, H ;
Itoh, Y ;
Newton, RC ;
Magolda, RL ;
Trzaskos, JM ;
Hollis, GF ;
Arner, EC ;
Burn, TC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (33) :23443-23450
[2]   Inhibition of bovine nasal cartilage degradation by selective matrix metalloproteinase inhibitors [J].
Bottomley, KM ;
Borkakoti, N ;
Bradshaw, D ;
Brown, PA ;
Broadhurst, MJ ;
Budd, JM ;
Elliott, L ;
Eyers, P ;
Hallam, TJ ;
Handa, BK ;
Hill, CH ;
James, M ;
Lahm, HW ;
Lawton, G ;
Merritt, JE ;
Nixon, JS ;
Rothlisberger, U ;
Whittle, A ;
Johnson, WH .
BIOCHEMICAL JOURNAL, 1997, 323 :483-488
[3]  
DELUCA S, 1980, J BIOL CHEM, V255, P6077
[4]  
FLANNERY CR, 1992, J BIOL CHEM, V267, P1008
[5]  
FOSANG AJ, 1991, J BIOL CHEM, V266, P15579
[6]   DEVELOPMENT OF A CLEAVAGE-SITE-SPECIFIC MONOCLONAL-ANTIBODY FOR DETECTING METALLOPROTEINASE-DERIVED AGGRECAN FRAGMENTS - DETECTION OF FRAGMENTS IN HUMAN SYNOVIAL-FLUIDS [J].
FOSANG, AJ ;
LAST, K ;
GARDINER, P ;
JACKSON, DC ;
BROWN, L .
BIOCHEMICAL JOURNAL, 1995, 310 :337-343
[7]   Aggrecan is degraded by matrix metalloproteinases in human arthritis - Evidence that matrix metalloproteinase and aggrecanase activities can be independent [J].
Fosang, AJ ;
Last, K ;
Maciewicz, RA .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (10) :2292-2299
[8]   Degradation of cartilage aggrecan by collagenase-3 (MMP-13) [J].
Fosang, AJ ;
Last, K ;
Knauper, V ;
Murphy, G ;
Neame, PJ .
FEBS LETTERS, 1996, 380 (1-2) :17-20
[9]   Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis [J].
Glasson, SS ;
Askew, R ;
Sheppard, B ;
Carito, B ;
Blanchet, T ;
Ma, HL ;
Flannery, CR ;
Peluso, D ;
Kanki, K ;
Yang, ZY ;
Majumdar, MK ;
Morris, EA .
NATURE, 2005, 434 (7033) :644-648
[10]   SPECIFIC INTERACTION OF HYALURONIC-ACID WITH CARTILAGE PROTEOGLYCANS [J].
HARDINGHAM, TE ;
MUIR, H .
BIOCHIMICA ET BIOPHYSICA ACTA, 1972, 279 (02) :401-+